Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Genosity Inks Deal With Gemini Therapeutics to Develop Assay for AMD Clinical Trial Patient Selection

Genosity Inks Deal With Gemini Therapeutics to Develop Assay for AMD Clinical Trial Patient Selection

Dec 16, 2020
|
staff reporter

NEW YORK — Genosity said on Wednesday that it has signed an agreement to develop a molecular diagnostic for use in selecting patients for a clinical trial of a dry age-related macular degeneration (AMD) drug candidate under development by Gemini Therapeutics.

Gemini's drug, called GEM103, is designed for dry AMD in patients with disease-associated complement factor H (CFH) loss-of-function gene variants.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

What's It Called?

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

Twin COVID-19 Studies

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

PNAS Papers on Positive Epistasis in Cystic Fibrosis, Tiger Rattlesnake Genome, More

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  2. Lucira Health Files for $115M IPO

  3. JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

  4. Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan

  5. Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.